RT Journal Article
SR Electronic
T1 Impact of Fluoropyrimidine and Oxaliplatin-based Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 593
OP 601
DO 10.21873/invivo.12296
VO 35
IS 1
A1 YUKA OKADA
A1 TSUYOSHI OZAWA
A1 TAMURO HAYAMA
A1 KOHEI OHNO
A1 MITSUO TSUKAMOTO
A1 YOSHIHISA FUKUSHIMA
A1 RYU SHIMADA
A1 KEIJIRO NOZAWA
A1 KEIJI MATSUDA
A1 YOJIRO HASHIGUCHI
YR 2021
UL http://iv.iiarjournals.org/content/35/1/593.abstract
AB Background/Aim: To evaluate the benefits of the addition of oxaliplatin (OX) to fluoropyrimidine (FP)-based neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancers (LARCs). Patients and Methods: We performed retrospective analyses comparing the pathological complete response (pCR) rate, overall survival (OS), recurrence-free survival (RFS), and local recurrence-free survival (LRFS) between FP-based and FP+OX-based CRT groups and for patients who had completed the CRT. Results: One hundred patients were included in the analyses: the pCR rate, OS, RFS, and LRFS were similar between these groups. The FP+OX group showed significantly more frequent incompleteness of the CRT compared to the FP group (p=0.049). Among the patients who had completed the CRT, the FP+OX group demonstrated significantly improved LRFS compared to the FP group (p=0.048). Conclusion: The addition of OX to an FP regimen in neoadjuvant CRT for LARC may reduce local recurrence in patients who have achieved good compliance to CRT.